ViewRay Inc. began a phase III randomized controlled trial titled “Locally Advanced Pancreatic cancer treated with ABLATivE stereotactic MRI-guided adaptive radiation therapy”—also known as LAP-ABLATE—which will compare stand-alone multi-agent chemotherapy, which is the current standard of care for patients with locally advanced pancreatic cancer, to patients receiving a combination of chemotherapy and 5-fraction MRIdian stereotactic MR-guided adaptive radiotherapy.
Project Purple, a national nonprofit dedicated to empowering the fight against pancreatic cancer, is launching the Pancreatic Cancer Research Recovery Support Grant. The initiative provides up to two years of bridge or rescue funding for promising pancreatic cancer research projects that were disrupted due to administrative funding policy changes at major federal agencies such as the NIH, the Department of Defense, or the National Science Foundation.
